[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Orchestra Biomed Hldgs Inc (OBIO)

Orchestra Biomed Hldgs Inc (OBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 234,135
  • Shares Outstanding, K 59,881
  • Annual Sales, $ 33,480 K
  • Annual Income, $ -52,700 K
  • EBIT $ -55 M
  • EBITDA $ -54 M
  • 60-Month Beta 0.52
  • Price/Sales 7.12
  • Price/Cash Flow N/A
  • Price/Book 5.79

Options Overview Details

View History
  • Implied Volatility 178.52% (+50.66%)
  • Historical Volatility 51.75%
  • IV Percentile 25%
  • IV Rank 20.42%
  • IV High 874.43% on 03/03/26
  • IV Low 0.00% on 09/05/25
  • Expected Move (DTE 17) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 14
  • Volume Avg (30-Day) 110
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,955
  • Open Int (30-Day) 3,028
  • Expected Range 3.91 to 3.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 3
  • High Estimate $-0.28
  • Low Estimate $-0.38
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.70 +5.68%
on 05/15/26
4.24 -7.78%
on 05/07/26
+0.11 (+2.89%)
since 04/29/26
3-Month
3.70 +5.68%
on 05/15/26
4.89 -20.04%
on 03/10/26
-0.47 (-10.73%)
since 02/27/26
52-Week
2.20 +77.73%
on 09/24/25
5.42 -27.91%
on 11/26/25
+0.96 (+32.54%)
since 05/28/25

Most Recent Stories

More News
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference

NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 3.91 (-1.76%)
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking...

LGND : 231.96 (-1.15%)
MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026  Orchestra BioMed and Medtronic plc. (NYSE: MDT, “Medtronic”), the...

MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest...

LGND : 231.96 (-1.15%)
MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval...

MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension...

MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”)  set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an ...

MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’...

MDT : 73.75 (-0.08%)
OBIO : 3.91 (-1.76%)
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 3.91 (-1.76%)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 3.91 (-1.76%)

Business Summary

Orchestra BioMed Inc. is a biomedical company accelerating high-impact technologies to patients. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy(TM)for the treatment of hypertension and Virtue(R) Sirolimus AngioInfusion(TM) Balloon for the treatment of atherosclerotic...

See More

Key Turning Points

3rd Resistance Point 4.10
2nd Resistance Point 4.05
1st Resistance Point 3.98
Last Price 3.91
1st Support Level 3.87
2nd Support Level 3.82
3rd Support Level 3.75

See More

52-Week High 5.42
Fibonacci 61.8% 4.19
Last Price 3.91
Fibonacci 50% 3.81
Fibonacci 38.2% 3.43
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.